---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-047156"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2023-10-05T23:59:59+00:00"
generated_at: "2026-06-10T04:21:45.114296+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eterna receives Nasdaq delisting notice for audit committee non-compliance; director Fiore resigns

## Summary
- Nasdaq notified Eterna on Oct 3, 2023 that audit committee no longer meets minimum three-member/independence requirement after Binder and Wagner resignations.
- Cure period: until earlier of next annual meeting or Aug 9, 2024; if meeting before Feb 5, 2024, compliance due by Feb 5, 2024.
- Director Gregory Fiore resigned Oct 4, 2023; not due to any disagreement with the company.
- Nasdaq closed prior deficiency on independent director/audit/comp committee rules following appointment of Dorothy Clarke on Aug 31 and Sep 26, 2023.
- Company evaluating director candidates to regain compliance; listing continues under symbol ERNA on Nasdaq.

## SEC filing metadata
- accession: 0001140361-23-047156
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2023-10-05T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036123047156/0001140361-23-047156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036123047156/ef20011972_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-047156
- JSON: https://secwatch.observer/filing/0001140361-23-047156.json
- Plain text: https://secwatch.observer/filing/0001140361-23-047156.txt

## Key facts
- Listing & Compliance Notices
  Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(4)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: audit committee
  - Rules: 5605, 5605(c)(4)
  source text: October 3, 2023, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) stating that, as a result of the previously disclosed resignations of Mr. Brant C. Binder and Dr. Richard W. Wagner from the Company’s board of directors and audit committee, the Company is no longer in compliance with Nasdaq Listing Rule 5605, which, in relevant part, requires the audit committee to consist of at least three members, each of whom must be an independent director under the Nasdaq Listing Rules
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123047156/0001140361-23-047156-index.htm
- Executive change
  Gregory Fiore resigned as Director at Ernexa Therapeutics Inc..
  - Action: resigned
  - Role: Director
  source text: O n October 4, 2023 Gregory Fiore resigned from the Company’s board of directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123047156/0001140361-23-047156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.